The primary objective of this study is to compare the efficacy of antecedent intravitreal anti-vascular endothelial growth factor therapy vs. Ozurdex in reducing post-cataract surgery related macular edema in patients with pre-existing diabetic macular edema.
In patients with pre-existing diabetic macular edema, anti-vascular endothelial growth factor therapy (Bevacizumab, ranibizumab, or aflibercept) will be compared to Ozurdex therapy administered 1 week prior to phacoemulsification cataract extraction. Spectral domain optical coherence tomography and visual acuity will be acquired at 1 week, 1 month, 2 months, and 3 months following cataract surgery.
|Treatment||bevacizumab, Aflibercept, ranibizumab, Ozurdex|
|Clinical Study Identifier||NCT03832179|
|Sponsor||Bay Area Retina Associates|
|Last Modified on||26 November 2020|
Select a piece of text and start making personal notes.
Congrats! You have your own personal workspace now.